The UK’s Medical Research Council has invested £50 ($67.3) million into the study of mitochondrial diseases for improved treatments.  

The new MRC Centre of Research Excellence in Mitochondrial Genome Therapeutics brings together leading experts from across disciplines to define how mutations in mitochondrial DNA (mtDNA) cause disease and translate that knowledge into therapies. 

No cure currently exists for mitochondrial diseases, a group of genetic disorders that affect around one in 5,000 people, leaving patients and their families facing significant unmet medical needs. 

Beyond inherited conditions, mtDNA mutations are increasingly linked to neurodegeneration, metabolic disease, cardiovascular failure and age-related deterioration. In affected individuals, mitochondrial dysfunction can contribute to severe disability, progressive decline and premature death. 

Project lead Professor Michal Minczuk of the University of Cambridge said: “The MRC CoRE will provide pioneering approaches to understanding and treating diseases caused by mutations in the mitochondrial genome. 

“We will be building a long-term UK research platform with the scale, expertise and infrastructure needed to position the UK as a global leader in mitochondrial genome therapeutics. 

“Our goal is to create the scientific foundations that will enable entirely new therapeutic strategies and offer renewed hope to patients and families affected by mitochondrial disease.” 

The MRC CoRE will harness emerging technologies to engineer the mitochondrial genome delivering advanced models of prevalent pathogenic mtDNA mutations. 

Led by the University of Cambridge, it will partner with the University of Birmingham, University of Manchester, Heidelberg University and the University of Queensland as well as the Imagine Institute in Paris and charities including leading UK charity the Lily Foundation and industry worldwide.